Compare Brunswick Corporation (BC) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Brunswick Corporation vs Summit Therapeutics Inc — how do they compare? Brunswick Corporation trades at $77.96 (market cap $5.04B), while Summit Therapeutics Inc trades at $15.38 (market cap $12.01B). The key difference: Summit Therapeutics Inc is far larger — about 2.4× Brunswick Corporation's market cap, and Brunswick Corporation pays a 2.27% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| BC | SMMT | |
|---|---|---|
Market Cap | $5.04B | $12.01B |
Sector | Consumer Cyclical | Health |
52-Week High | $89.22 | $29.32 |
52-Week Low | $56.64 | $13.05 |
Enterprise Value | $7.20B | $11.43B |
Dividend Yield | 2.27% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BC's stock trades at $76.95, down 1.22% on the day, with a bearish technical signal and support near $76. The company reported a net loss of $137.30 million in 2025 despite revenue of $5.36 billion, though recent earnings beat expectations. Analyst consensus is strongly bullish with a $86.40 price target, and the company continues expanding its Freedom Boat Club business.
The outlook is mixed: strong analyst support and operational cash flow of $562.10 million in 2025 provide upside potential, but negative profit margins and high P/E of 73.92 pose valuation risks. Investors face headwinds from profitability challenges despite positive sentiment from Wall Street.
Summit Therapeutics (SMMT) trades at $15.30, showing modest daily gains of 0.33%. The stock faces bearish technical signals with negative cash flows and substantial losses (-$1.08B net income in 2025). Recent developments include the sale of Phase III asset ridinilazole and positive clinical trial results for ivonescimab. Analyst sentiment remains optimistic with 67% buy ratings and a $15.57 consensus target, though financial metrics show concerning profitability with -270.95% ROE.
SMMT presents a high-risk, catalyst-driven opportunity with binary outcomes dependent on clinical success. The company's heavy reliance on ivonescimab development creates significant upside potential but also substantial execution risk. Negative cash flow trends and persistent losses require careful monitoring of upcoming Q2 2026 earnings and clinical milestones for directional clarity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Brunswick Corporation
Brunswick Corp is the leader in several recreational sectors. The firm is the leading boat manufacturer, and its brands include Mercury and Mariner outboard engines
Read more on BC →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
